Genentech enters into $405m anticancer drug deal
Genentech and Inotek have entered into a strategic alliance in which they will concentrate on the discovery, development and commercialisation of PARP inhibitors for cancer - a class of drug that has demonstrated high efficacy in treating tumour growth.